Ascent Group’s Ironwood Pharmaceuticals IRWD Stock Holding History

Ascent Group’s Portfolio IRWD Stock Details IRWD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$58.1K	Buy	+14,638	New	+$61.1K	﹤0.01%	806

Other funds holding IRWD

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

Ritholtz Wealth Management New York $6.96B AUM 24% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

CWA Asset Management Group Naples, Florida $3.39B AUM 25.16% 1-Year Est. Return

Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $54.1B AUM 39.29% 1-Year Est. Return

Ascent Group's IRWD Position: Q3 2026 in Review

Ascent Group opened a new position in Ironwood Pharmaceuticals (IRWD) in Q3 2026: 14,638 shares worth $58.1K. The stake represents ﹤0.01% of the portfolio and ranks #806 among its holdings.

84 funds tracked by Wall St. Rank hold IRWD as of Q3 2026.

Ascent Group held 14,638 shares of Ironwood Pharmaceuticals worth $58.1K as of Q3 2026.
Ironwood Pharmaceuticals was a new Ascent Group position in Q3 2026.
Ironwood Pharmaceuticals made up ﹤0.01% of Ascent Group's portfolio in Q3 2026, its #806 holding.
84 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q3 2026.

Based on Ascent Group's 13F filing for Q3 2026, filed 30 Oct 2026.